Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Health (NASDAQ:COSM) reported Q1 2025 results showing significant improvement in profitability metrics despite revenue decline. Revenue decreased 5.98% to $13.71M, while gross profit surged 53.70% to $2.05M. The company achieved notable improvements in operational efficiency with gross margin expanding by 581 basis points to 14.95%. Operating expenses declined 9.05% to $2.88M through strategic cost reductions. The company returned to profitability on an adjusted basis, with Adjusted EBITDA of $0.37M (up 157.8%) and Adjusted Net Income of $0.28M (up 139.4%). Operating cash burn improved dramatically, decreasing 94.5% to -$0.19M. The balance sheet showed strength with total assets increasing 5.3% to $57.2M and stockholders' equity rising by $1.42M. CEO Greg Siokas demonstrated confidence by personally investing over $1.3M in company shares.

Cosmos Health (NASDAQ:COSM) has received a new order for 80,000 units of its Sky Premium Life products from Pharmalink for distribution in the United Arab Emirates (UAE). This follows the successful sell-out of their initial 130,000-unit order. The orders are part of an exclusive distribution agreement with Pharmalink, who handles all sales, marketing, regulatory affairs, logistics, and distribution activities in the UAE. The company aims to exceed 3 million units in cumulative orders over the first five years of the partnership. CEO Greg Siokas highlighted the growing momentum of Sky Premium Life nutraceuticals in the UAE market.

Cosmos Health (NASDAQ:COSM) has received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company now has until November 3, 2025, to meet the $1.00 minimum bid price threshold. This extension follows the initial 180-day compliance period that expired on May 5, 2025, after COSM was first notified of non-compliance on November 6, 2024.

The second compliance period was granted as Cosmos Health meets all other Nasdaq Capital Market listing requirements. To regain compliance, the company's stock must maintain a closing bid price of at least $1.00 for a minimum of 10 consecutive business days during this period.

CEO Greg Siokas expressed confidence in meeting the listing requirements within the extended timeframe while focusing on executing strategic priorities.

Cosmos Health CEO Greg Siokas has significantly increased his stake in the company by purchasing 1,466,764 common shares valued at $526,000 through five transactions between April 21-24, 2025. This recent investment brings his total beneficial ownership to 5,582,066 shares.

Over the past five months, Siokas has invested more than $1.3 million, adding over 2.7 million shares to his holdings. His total investment in the company since inception now exceeds $18 million.

As a vertically integrated global healthcare group, Cosmos Health focuses on:

• Innovative R&D
• Proprietary pharmaceutical and nutraceutical brands
• Healthcare product manufacturing and distribution
• Telehealth platform operations

The CEO expressed confidence in the company's direction and commitment to creating shareholder value.

Cosmos Health (NASDAQ:COSM) reported its full-year 2024 financial results, showing a 2% revenue increase to $54.43 million from $53.38 million in 2023. The company achieved a significant 24.16% reduction in operating expenses to $19.86 million, including a 40.26% cut in administrative expenses and 71% decrease in marketing costs.

Gross margin slightly declined to 7.92% from 8.15% in 2023. The company reported an Adjusted EBITDA of negative $3.73 million, compared to positive $0.06 million in 2023. Total assets decreased by 17.72% to $54.31 million, while maintaining a 55% liabilities-to-assets ratio.

Key developments include AI-driven patent filings for multiple diseases, advancement of weight management solution CCX0722, expansion of manufacturing capabilities, and securing a €2.2 million bond loan at 2.95% interest plus Euribor. The company also expanded its Sky Premium Life brand globally and integrated cryptocurrency as treasury reserve assets.

Cosmos Health (NASDAQ:COSM) announces completion of manufacturing upgrades at its subsidiary Cana Laboratories and signs a significant 5-year contract manufacturing agreement with Pharmex S.A. The deal involves producing 300,000 bottles annually of the antiseptic drug AMBITASOL 1L, totaling 1.5 million units over the contract period.

Cana Laboratories, acquired by Cosmos Health in July 2023, operates an Athens facility licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA). The facility can manufacture various pharmaceuticals including tablets, capsules, syrups, nasal sprays, creams, gels, antiseptics, and biocides.

This agreement with Pharmex, a specialty pharmaceutical company established in 1981, represents part of Cosmos Health's strategy to expand its high-margin contract manufacturing business.

Cosmos Health (NASDAQ:COSM) has announced the launch of its Sky Premium Life food supplements brand in Albania through a partnership with Pharma Cell. The company has secured an initial annual order worth $300,000 from Pharma Cell, which will serve as the distributor in Albania.

Pharma Cell, based in Tirana, is a pharmaceutical company specializing in import and export of food supplements. Founded in 2021 by CEO Elvis Punmira, the company has established a growing network of pharmacies and healthcare professionals across Albania.

Cosmos Health (NASDAQ:COSM) has announced a significant expansion of its Sky Premium Life nutraceutical brand with the addition of 60 new SKUs, bringing the total product count to over 150. The expansion supports the brand's global growth through new distribution agreements across multiple territories, including presence in pharmacies and international retail chains like Holland & Barrett, as well as e-commerce platforms like Amazon.

The company's R&D department has developed several new products, including:

• Kakadu Plum with high vitamin C concentration
• Good Morning & Good Night energy and sleep formulations
• ZenBlend for relaxation and sleep
• Skinovate for skin rejuvenation
• Electrolytes in cherry and lemon flavors

Cosmos Health (NASDAQ:COSM) has announced it will not proceed with its planned offering under Form S-1 until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The company, which operates as a diversified healthcare group focusing on pharmaceutical and nutraceutical brands, manufacturing, distribution, and telehealth services, has postponed any potential offering until after the annual financial reporting is complete.